International Journal of Hematological Disorders
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
International Journal of Hematological Disorders. 2017, 3(1), 3-6
DOI: 10.12691/ijhd-3-1-2
Open AccessReview Article

Bone Targeted Therapy in Multiple Myeloma

Hiroko Nishida1,

1Department of Pathology, Keio University, School of Medicine, Tokyo, Japan

Pub. Date: March 29, 2017

Cite this paper:
Hiroko Nishida. Bone Targeted Therapy in Multiple Myeloma. International Journal of Hematological Disorders. 2017; 3(1):3-6. doi: 10.12691/ijhd-3-1-2


The interaction between multiple myeloma (MM) cells and cellular components and its (BM) microenvironment promotes MM cell growth and osteolytic bone destruction. Osteolytic bone disease, characterized by bone pain, increased risk of pathologic fractures, tumor-induced hypercalcemia, is a frequent complication of MM patients. These skeletal-related events (SREs) decrease their quality of life and reduce their survival. Therefore, therapeutic strategies targeting the interplay between MM cells and the BM cellular components, including osteoclasts (OCs), stromal cells as well as MM cells themselves are necessary not only to attain tumor regression but to reduce its associated bone disease. The goal of bone-targeted therapy in MM is to reduce or delay the incidence of SREs and to improve the quality of life in affected patients. Currently, several novel agents are in the clinical trials.

multiple myeloma bone marrow microenvironment osteoclast skeletal-related events bone-targeted therapy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol. 2004; 32(8): 685-91.
[2]  Yaccoby S, Wezeman MJ, Henderson A, et. al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004; 64(6): 2016-23.
[3]  Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012; 18(2): 326-35.
[4]  Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol. 2001; (38): 276-85.
[5]  Melton LJ, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005; 20: 487-93.
[6]  Abe M, Hiura K, Wilde J, yet al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104: 2484-91.
[7]  Silbermann R, Roodman GD. Myeloma bone disease: Pathophysiology and management. 2013; 12(2): 59-69.
[8]  Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23: 435(3)-41.
[9]  Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab. 2010; 28(3): 244-50.
[10]  Hideshima T, Mitsiades C, Tonon G, et al. Understandimng multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targetes. Nat Rev Cancer. 2007; 7(8): 585-98.
[11]  Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastgenesis and bone disease. Trends Mol Med. 2006; 12: 17-25.
[12]  Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005; 65(5): 1700-9.
[13]  Tanaka Y, Abe M, Hiasa M, Oda A, et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth with bone resorption: a role for vascular endothelial growth factor and osteopontin. Clin Cancer Res. 2007; 13(3): 816-23.
[14]  Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoproteogerin in multiple myeloma bone disease. Blood. 2003; 101(6): 2094-8.
[15]  Abe M, Hiura K, Ozaki S, et al. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab. 2009; 27(1): 16-23.
[16]  Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. 2000; 96(2): 671-5.
[17]  Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 20004; 103(6): 2308-15.
[18]  Moreaux J, Legouffe E, Jourdan E. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004; 103(8): 3148-57.
[19]  Tai YT, Li X, Breitkreutz I, et al. Role of B-cell-activating actor in adhesion and growth of human myeloma cells in the bone marrow microenvironment. Can Res. 2006; 66(13): 6675-82.
[20]  Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006; 42(11): 1581-90.
[21]  Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood. 2009; 115(1): 140-9.
[22]  Gunn WG, Conley A, Deininger L, et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006; 24(4): 986-91.
[23]  Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist against DKK1 in the development of osteolytic lesions in multiple myeloma. N Eng J Med. 2003. 349(26); 2483-94.
[24]  Giuliani N, Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma. 2007; 48(12): 2323-9.
[25]  Terpos E, Roodman GD. Dimopoulos MA. Optimal use of bisphosphonates in patients with multiple myeloma. Blood. 2013; 121(17): 3325-8.
[26]  Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesion of multiple myeloma. A phase III, double-blind, comparative trial. Cancer J. 2001; 7(5): 377-87.
[27]  Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications with advanced multiple myeloma or breast carcinoma: A randomized, double-blind multicenter, comparative trial. Cancer. 2003; 98(8): 1735-44.
[28]  Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007; 56(6): 390-6.
[29]  Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung cancer and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100(12): 2613-21.
[30]  Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial o zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458-68.
[31]  Kohno N, Aogi K, Minami H, et al. Zoredronic acid significantly reduces skeletal complications compared with placebo in Japanese woman with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clini Oncol. 2005; 23(15): 3314-21.
[32]  Chang JT, Green L, Beitz J, et al. Renal failure with the use of zoredronic acid. N Eng J Med. 2003; 349(17): 1676-9.
[33]  Walter C, Al-Nawas B, Frickhofen N, et al. Prevalence of bisphosphonates associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010;6:11.
[34]  Castellano D, Sepulveda JM, Escobar IG, et al. The role of RANKL-ligand inhibition in cancer: the story of denosumab. The Oncologist. 2011, 16, 136-45.
[35]  Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid or the treatment of bone metastasis in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35): 5132-9.
[36]  Irelli A, Cocciolone V, Cannita K et al. Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. Bone. 2016; 87: 169-175.
[37]  Body JJ, Facon T, Coleman RE, et l. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4): 1221-8.
[38]  Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011; 377(9768): 813-22.
[39]  Hutton B, Morretto P, Emmenegger U, et al. Bone-targeted agenet use for bone metastases from breast cancer and prostate cancer: A patient survey. J Bone Oncol. 2013; 2(3): 105-9.
[40]  LeVasseur N, Clemons M, Huttom B, et al. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systemic review of randomized controlled trials. Cancer Treat Rev. 2016; 50: 183-93.
[41]  Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastasis in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011. 29(9), 1125-32.
[42]  Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegrin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98(13):3534-40.
[43]  Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastgenesis and inhibits the interaction of multiple myeloma and osteoclasts. Blood. 2007; 110(10): 3744-52.
[44]  Von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastgenesis. Leukemia. 2007; 21(9): 2025-34.
[45]  Giuliani N, Morandi F, Tagliferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007; 110(1): 334-8.
[46]  Nishida H, Suzuki H, Madokoro H, et. Al. Blockade of CD26 signaling inhibits human osteoclast development. J Bone Miner Res. 2014, 29(11) 2439-55.
[47]  Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009; 24(3): 425-36.
[48]  Fulcininti M, Tassone P, Hideshima T, et al. Anti-DKK1 mab(BHQ) as apotential therapeutic agent for multiple myeloma. Blood. 2009; 14(2): 371-9.
[49]  Takeuchi K, Abe M, Hiasa M, et al. TGF-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010; 5: e9870.
[50]  Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010; 107(11): 5124-9.